EXAS Exact Sciences Inc. Expected net earnings per share growth this year
Kevin Conroy's team at Exact Sciences (EXAS) aims to solidify the dominance of its key test and monetize new developments, while year-over-year EPS growth percentages reflect profit dynamics, where the current metric equals 94.80. Insurance guarantees revenue stability, rendering diagnostics crisis-resistant. However, geopolitics limit technology exports and disrupt the supply of critical reagents.
Financial and market metric breakdowns for Exact Sciences (EXAS)
- current quotes and average value forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Total Debt to Capital Exact Sciences|EXAS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio exactsciences.com|EXAS - Company Total Debt|Debt to Book Capital Exact Sciences Inc.|EXAS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Exact Sciences|Interim Coverage Ratio exactsciences.com
- company profitability and valuation multiples indicators:
EXAS - Net Profit|Future Profit Exact Sciences|EXAS - P/E Multiple|Market Cap to Projected Earnings Exact Sciences Inc.|EXAS - PEG Multiple|Company Value to EBITDA Exact Sciences Inc.|EXAS - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Exact Sciences|EXAS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months exactsciences.com|EXAS - Earnings growth in current year|Expected net earnings per share growth next year Exact Sciences
Summary company analysis:Exact Sciences Corp - EXAS
To build a defensive portfolio, fundamental screening requires precise measurement of year-over-year net income per share dynamics. This metric captures EPS growth rates, reflecting the expense management efficiency of Exact Sciences (EXAS), including reagent utilization costs and test kit logistics, which clearly demonstrates annual EPS progress within GURU.Markets analytics.
Key competitors
A - Expected net earnings per share growth this year|Earnings per share growth in current year Quest|Illumina Platform (ILMN) - Expected net earnings per share growth this year|Earnings growth in current year RVTY|BIO - Earnings per share growth rate in current year|Anbio - Net earnings per share growth this year|SHC: Earnings per share growth this year|QuidelOrtho Corp - Earnings growth in current year|OPK - Earnings growth in current year|CDNA: Earnings growth in current year|Net earnings per share growth this year maravai.com|Net earnings per share growth this year FLGT|LAB (Standard BioTools Inc) - Net earnings per one share growth for the current year|Net earnings per share growth this year CTKB (Cytek Bio)|OSUR (OraSure Corp) - Earnings per share increase in current year|Earnings per share growth in current year Exagen XGN|Expected net earnings per share growth this year mdxhealth.com (MDXH)|Lucid Diagnostics - Earnings growth in current year|Prenetics Global (PRE) - Net earnings per share growth this year|IMDX: Earnings growth in current year|TRIB - Expected net earnings per share growth this year|PRPH (ProPhase Labs, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year ainos.com AIMD|Earnings per share growth in current year Co-Diagnostics (CODX)|Heart Test Laboratories, Inc. - Earnings per share growth this year|Earnings growth in current year BMRA (Biomerica, Inc)|CDIO - Net earnings per share growth this year|Onconetix, Inc. - Earnings growth in current year|Earnings per share growth rate in current year viraxbiolabs.com|Bluejay Diagnostics, Inc. (BJDX) - Earnings per share growth in current year|AWH - Expected net earnings per share growth this year|AXDX (Accelerate Diagnostics, Inc) - Earnings growth in current year|Earnings per share growth rate in current year CENTOGENE N.V. CNTG|Net earnings per share growth this year ENZ (Enzo Biochem, Inc.)|fresh2.co - Earnings per share growth this year|Earnings growth in current year GENE (Genetic Technologies Limited)|Earnings growth in current year 23andMe Holding Co ME|PMD - Earnings per share growth in current year
